ArticleJournal of virology2026
A murine coronavirus infection platform identifies proviral and proinflammatory activities of SARS-CoV-2 accessory protein 7a.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related sarbecoviruses encode a set of accessory proteins (3a, 3b, 6, 7a, 7b, 8, 9b, and 10) that control host responses to infection and promote virus growth. Of these accessory proteins, 7a is set apart by its intracellular localization near CoV budding sites and its incorporation into secreted virions. To investigate 7a functions during CoV infections under biosafety level 2 conditions, we constructed recombinant mouse hepatitis viruses (rMHVs) (rMHV strain A59) that express sarbecovirus 7a genes. Comparative infections revealed that 7a increased viral replication and viral output in immortalized murine cell cultures and in primary bone marrow-derived macrophages (BMDMs). This proviral effect was independent of a previously reported 7a-mediated interferon antagonizing activity. 7a is a type I transmembrane protein with a short cytoplasmic tail that operates in subcellular trafficking and signal transduction. To further elucidate tail functions, we generated a set of rA59 viruses expressing substitutions in the tail di-lysine motifs. Several substitutions reduced 7a proviral activities; notably, the K119A change in rA59-7a-KRATE eliminated 7a support of virus yield. The K119A change also reduced mouse-adapted SARS-CoV-2 virus yields in infected BALB/c mice. 7a expression was proinflammatory in BMDMs, as measured by cytokine arrays. Cytoplasmic tail substitutions tempered these proinflammatory responses, implying connections with proviral activities. SARS-CoV-2-infected macrophages have been implicated in inflammatory COVID-19, and these findings point to 7a cytoplasmic tails as potential contributors to cytokine-mediated disease. IMPORTANCE: This study shows that SARS-CoV-2 accessory protein 7a promotes infection of a phylogenetically distinct embecovirus and, in doing so, elicits proinflammatory and potentially disease-relevant host responses. The proviral and proinflammatory activities were traced in part to a short 7a cytoplasmic tail. The findings localize and highlight a specific proviral component in a sarbecovirus accessory protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.